Abstract:BACKGROUND:The epidermal growth factor receptor (EGFR) is involved in the development and progression of lung cancer. Somatic EGFR mutations are predictors of response to treatment with EGFR tyrosine kinase (TK) inhibitors (TKIs) for lung cancer, especially among never smokers. EGFR mutations may occur independently of other genetic alterations.METHODS:The authors sequenced the EGFR-TK domain and the K-ras and p53 genes from lung tumor tissues from 44 never smokers and 46 smokers. A case-control study also was conducted to examine the relationship between an EGFR single nucleotide polymorphism in the TK domain and the lung cancer through a multivariate logistic regression analysis. In addition, the authors compared cell growth kinetics, EGFR-TKI sensitivity by MTT, and activation of signaling molecules by immunoblot in lung cancer cell lines with and without EGFR-TK mutations.RESULTS:EGFR-TK mutations were more frequently observed in never smokers (25%) than in smokers (2.2%) (p = 0.001). Excluding cases with a K-ras mutation, the frequency of EGFR-TK domain mutation was still significantly higher in never smokers than in smokers, 26.2% versus 4.5% (p = 0.046). EGFR-TK mutations and K-ras mutations (p = 0.015), and p53 and K-ras mutations (p = 0.015) were mutually exclusive, but p53 and EGFR-TK mutations were not (p = 1.00). During sequencing of the EGFR-TK domain in tumors, an EGFR polymorphism (G2607A) was identified. The genotype AA and AA + AG occurred at a significantly higher frequency in lung cancer cases (n = 122) when compared with controls (n = 147) (odds ratio, 3.39 and 2.67; 95% confidence interval, 1.41-8.17 and 1.17-6.08, p = 0.006 and p = 0.02, respectively). This polymorphism was found independently of EGFR-TK mutations in lung cancer cases, indicating that it does not predispose to mutations. In vitro, lung cancer cell lines with EGFR-TK mutations also did not contain K-ras mutations and displayed a lower growth rate (50%, p = 0.013) than EGFR-TK wild-type cell lines. EGFR-TK mutant cell lines were more sensitive to both gefitinib and erlotinib, although relative sensitivity to erlotinib compared with wild-type was less pronounced than for gefitinib. Cell lines with a lower growth rate also expressed higher levels of E-cadherin than faster growing cell lines.CONCLUSIONS:EGFR-TK mutation frequency is high in never-smoking lung cancer patients and is exclusive of mutation in K-ras but not p53. In addition to somatic EGFR-TK mutations that arise in lung tumors, germline variation in the EGFR-TK domain might also be associated with an increased risk of lung cancer. Somatic EGFR-TK mutations alter cell biology and response to EGFR-TKIs and may be mutation specific.

Mechanism for Activation of Mutated Epidermal Growth Factor Receptors in Lung Cancer

Structures of an Eph receptor tyrosine kinase and its potential activation mechanism.

Data from Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants is Associated with Asymmetric Dimerization

Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation

Mechanisms for Kinase-mediated Dimerization of the Epidermal Growth Factor Receptor

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

Structures Of Lung Cancer-Derived Egfr Mutants And Inhibitor Complexes: Mechanism Of Activation And Insights Into Differential Inhibitor Sensitivity

Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer

Molecular Mechanism Study of EGFR Allosteric Inhibitors Using Molecular Dynamics Simulations and Free Energy Calculations

Supplementary Figures 1 - 10 from Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants is Associated with Asymmetric Dimerization

A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology

Aberrant Epidermal Growth Factor Receptor Signaling And Enhanced Sensitivity To Egfr Inhibitors In Lung Cancer

Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers

Mutation Specific Functions of Egfr Result in A Mutation-Specific Down Stream Pathway Activation

Geometrical Features of Epidermal Growth Factor Receptor-Related Dimers Reveal the Mechanisms of Drug Resistance in Lung Cancer Patients

High Expression Of Erbb Family Members And Their Ligands In Lung Adenocarcinomas That Are Sensitive To Inhibition Of Epidermal Growth Factor Receptor

Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor.

Effect of Double Mutations T790M/L858R on Conformation and Drug-Resistant Mechanism of Epidermal Growth Factor Receptor Explored by Molecular Dynamics Simulations

Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication.

The T790m Mutation in Egfr Kinase Causes Drug Resistance by Increasing the Affinity for Atp

EGFR Phosphorylation of DCBLD2 Recruits TRAF6 and Stimulates AKT-promoted Tumorigenesis